Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2023

Stockholders' Equity Note [Abstract]

Stock-based Compensation Expense

The stock-based compensation related to our stock-based awards and employee stock purchase plan for the three and six months ended June 30, 2023 and 2022 is as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Cost of net revenues	$	1,901	$	1,614	$	3,708	$	3,128
Selling, general and administrative	29,002		26,491		57,693		51,216
Research and development	6,957		6,035		14,194		11,417
Total stock-based compensation	$	37,860	$	34,140	$	75,595	$	65,761

Summary Of Restricted Stock Units

A summary for the six months ended June 30, 2023 is as follows:

	Number of Shares Underlying RSUs (in thousands)	Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Unvested as of December 31, 2022	489	$	427.23
Granted	502	316.03
Vested and released	(191)	380.55
Forfeited	(27)	394.18
Unvested as of June 30, 2023	773	$	367.66	1.8	$	273,404

Summary Of Market-performance Based Restricted Stock Units

The following table summarizes the MSU performance activity for the six months ended June 30, 2023: 

	Number of Shares Underlying MSUs (in thousands)	Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Unvested as of December 31, 2022	144	$	725.73
Granted 1	82	629.53
Vested and released	(25)	392.67
Forfeited	(41)	392.67
Unvested as of June 30, 2023	160	$	812.75	1.9	$	56,670

Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

The fair value of the option component of the 2010 Purchase Plan shares was estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions:

	Six Months Ended June 30,
	2023			2022
Expected term (in years)	1.0			1.5
Expected volatility	56.7		%	48.6		%
Risk-free interest rate	4.6		%	1.0		%
Expected dividends	—			—
Weighted average fair value at grant date	$	105.75		$	196.97